- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Leverage Leaders
U.S. Pharmaceuticals & Biotech Leverage Leaders
Results
59
59 companies
Natera
Market Cap: US$22.1b
A diagnostics company, provides molecular testing services worldwide.
NTRA
US$160.12
7D
0.2%
1Y
35.2%
Alkermes
Market Cap: US$4.6b
A biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
ALKS
US$28.85
7D
5.2%
1Y
2.5%
Protagonist Therapeutics
Market Cap: US$3.5b
A biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
PTGX
US$56.25
7D
3.2%
1Y
35.5%
Avidity Biosciences
Market Cap: US$5.7b
A biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).
RNA
US$44.02
7D
-4.8%
1Y
-1.9%
Centessa Pharmaceuticals
Market Cap: US$2.4b
A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.
CNTA
US$17.34
7D
1.3%
1Y
44.3%
Revolution Medicines
Market Cap: US$6.8b
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
RVMD
US$36.54
7D
1.3%
1Y
-19.3%
Medpace Holdings
Market Cap: US$13.0b
Provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
MEDP
US$462.14
7D
0.6%
1Y
18.7%
MoonLake Immunotherapeutics
Market Cap: US$3.4b
A clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
MLTX
US$52.66
7D
-4.0%
1Y
6.4%
Merus
Market Cap: US$5.0b
A clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
MRUS
US$63.65
7D
-0.2%
1Y
18.5%
Danaher
Market Cap: US$149.7b
Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
DHR
US$212.20
7D
3.1%
1Y
-21.9%
Akero Therapeutics
Market Cap: US$3.9b
Engages in the development of treatments for patients with serious metabolic diseases in the United States.
AKRO
US$47.60
7D
-0.9%
1Y
78.0%
NewAmsterdam Pharma
Market Cap: US$2.9b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
NAMS
US$24.45
7D
-2.2%
1Y
50.6%
Belite Bio
Market Cap: US$2.1b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$61.81
7D
-15.0%
1Y
24.6%
Repligen
Market Cap: US$7.0b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$123.50
7D
1.7%
1Y
-17.8%
Bio-Rad Laboratories
Market Cap: US$7.5b
Manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.
BIO
US$288.37
7D
5.0%
1Y
-9.5%
Summit Therapeutics
Market Cap: US$19.5b
A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
SMMT
US$25.35
7D
-1.3%
1Y
105.9%
BeOne Medicines
Market Cap: US$35.1b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$312.51
7D
8.5%
1Y
60.9%
Tarsus Pharmaceuticals
Market Cap: US$2.3b
A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
TARS
US$53.70
7D
4.6%
1Y
104.7%
Arcellx
Market Cap: US$4.0b
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
ACLX
US$72.00
7D
-0.7%
1Y
9.3%
Recursion Pharmaceuticals
Market Cap: US$2.4b
Operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States.
RXRX
US$5.09
7D
-5.9%
1Y
-28.9%
Crinetics Pharmaceuticals
Market Cap: US$2.8b
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
CRNX
US$29.43
7D
3.3%
1Y
-45.3%
Nuvalent
Market Cap: US$5.4b
A clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
NUVL
US$74.67
7D
-2.5%
1Y
-2.1%
CRISPR Therapeutics
Market Cap: US$5.2b
A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
CRSP
US$54.16
7D
-4.3%
1Y
10.4%